March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Experience With Intravitreal Bevacizumab In Pediatric Retinal Disorders
Author Affiliations & Notes
  • Johnathan D. Warminski
    Ophthalmology, UT Southwestern Medical Center, Dallas, Texas
  • Yu-Guang He
    Ophthalmology, UT Southwestern Medical Center, Dallas, Texas
  • Footnotes
    Commercial Relationships  Johnathan D. Warminski, None; Yu-Guang He, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 949. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Johnathan D. Warminski, Yu-Guang He; Experience With Intravitreal Bevacizumab In Pediatric Retinal Disorders. Invest. Ophthalmol. Vis. Sci. 2012;53(14):949.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The use of intravitreal bevacizumab (Avastin, Genentech)has expanded significantly for the treatment of multiple choroidal and retinal diseases in adults, leading to early use in pediatric patients. Evaluated is the experience with this medication in pediatric patients for both safety and efficacy

Methods: : Review of injections of intravitreal bevacizumab injections at Children's Medical Center, Dallas, TX and James W. Aston Ambulatory Care Center at UT Southwestern Medical Center in pediatric patients from 2007 to present. 7 eyes in 5 patients were identified who underwent a total of 39 intravitreal injections. Injections were performed with 1.25mg (0.05mL of 25 mg/mL) of bevacizumab intravitreally.

Results: : After the injections there was observable clinical improvement in visual acuity and clinical appearance. Additionally, there were no associated complications from the procedures and no apparent toxicity of the medication was observed during follow up assessment

Conclusions: : This series of 39 injections adds to the body of evidence that supports intravitreal bevacizumab as a safe and effective therapy,extends follow-up intervals, adds additional data to previous case series and describes an additional use for intravitreal bevacizumab

Keywords: retina 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.